KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Revenue (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Revenue for 13 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 33.23% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Dec 2025, up 128.21% year-over-year, with the annual reading at $14.1 million for FY2025, 128.21% up from the prior year.
  • Revenue hit $1.1 million in Q4 2025 for Arbutus Biopharma, up from $529000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $14.2 million in Q2 2022 to a low of $529000.0 in Q3 2025.
  • Historically, Revenue has averaged $4.4 million across 5 years, with a median of $2.8 million in 2021.
  • Biggest five-year swings in Revenue: crashed 77.09% in 2024 and later soared 522.19% in 2025.
  • Year by year, Revenue stood at $3.2 million in 2021, then surged by 94.79% to $6.2 million in 2022, then crashed by 65.65% to $2.1 million in 2023, then dropped by 26.62% to $1.6 million in 2024, then plummeted by 33.23% to $1.1 million in 2025.
  • Business Quant data shows Revenue for ABUS at $1.1 million in Q4 2025, $529000.0 in Q3 2025, and $10.7 million in Q2 2025.